UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Waystar Holding Corp. (NASDAQ:WAY – Free Report) by 13.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 169,608 shares of the company’s stock after selling 26,126 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.09% of Waystar worth $3,482,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Clarkston Capital Partners LLC bought a new stake in shares of Waystar in the 1st quarter worth about $22,917,000. Hsbc Holdings PLC bought a new position in shares of Waystar during the first quarter worth about $5,625,000. Bain Capital Venture Investors LLC acquired a new position in Waystar in the second quarter worth about $18,127,271. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in Waystar in the second quarter worth about $43,314,000. Finally, Perigon Wealth Management LLC bought a new stake in Waystar in the second quarter valued at about $878,000.
Waystar Stock Performance
Shares of NASDAQ WAY opened at $23.06 on Friday. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.36. The firm’s 50-day moving average price is $23.79 and its two-hundred day moving average price is $22.76. Waystar Holding Corp. has a 52-week low of $17.26 and a 52-week high of $40.35. The stock has a market capitalization of $4.42 billion, a P/E ratio of 32.94, a P/E/G ratio of 0.93 and a beta of 0.16.
Wall Street Analysts Forecast Growth
A number of research firms have commented on WAY. BMO Capital Markets reaffirmed an “outperform” rating on shares of Waystar in a report on Thursday, August 27th. Canaccord Genuity Group upped their price target on Waystar from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Barclays raised their price objective on Waystar from $25.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Wolfe Research raised shares of Waystar to an “outperform” rating in a report on Thursday, August 13th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $44.00 target price on shares of Waystar in a research note on Thursday, August 27th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.14.
Check Out Our Latest Analysis on Waystar
Insider Activity at Waystar
In related news, CEO Matthew Hawkins sold 82,500 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $25.97, for a total value of $2,142,525.00. Following the sale, the chief executive officer owned 1,804,794 shares of the company’s stock, valued at $46,870,500.18. This trade represents a 4.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 165,000 shares of company stock worth $4,206,524 in the last three months. 3.50% of the stock is currently owned by corporate insiders.
Waystar Profile
Waystar (NASDAQ:WAY) is a leading provider of cloud-based revenue cycle management and payment solutions for healthcare organizations. The company’s unified platform streamlines the entire financial continuum of patient care, from eligibility verification and claim submission to payment reconciliation and patient billing. By automating key processes and improving claim accuracy, Waystar helps providers reduce administrative overhead, accelerate cash flow and enhance overall revenue performance.
At the core of Waystar’s offering is a SaaS-based architecture that integrates seamlessly with existing electronic health record (EHR) systems and payer networks.
Read More
- Five stocks we like better than Waystar
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Waystar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waystar and related companies with MarketBeat.com's FREE daily email newsletter.
